JP2021534195A5 - - Google Patents
Info
- Publication number
- JP2021534195A5 JP2021534195A5 JP2021509764A JP2021509764A JP2021534195A5 JP 2021534195 A5 JP2021534195 A5 JP 2021534195A5 JP 2021509764 A JP2021509764 A JP 2021509764A JP 2021509764 A JP2021509764 A JP 2021509764A JP 2021534195 A5 JP2021534195 A5 JP 2021534195A5
- Authority
- JP
- Japan
- Prior art keywords
- hmga2
- formulation
- tgfβ
- expression
- patient
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721249P | 2018-08-22 | 2018-08-22 | |
| US62/721,249 | 2018-08-22 | ||
| PCT/US2019/047734 WO2020041607A1 (en) | 2018-08-22 | 2019-08-22 | Treatment of triple negative breast cancer with targeted tgf-b inhibition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534195A JP2021534195A (ja) | 2021-12-09 |
| JPWO2020041607A5 JPWO2020041607A5 (https=) | 2022-08-29 |
| JP2021534195A5 true JP2021534195A5 (https=) | 2022-08-29 |
Family
ID=69591342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021509764A Pending JP2021534195A (ja) | 2018-08-22 | 2019-08-22 | 標的ＴＧＦ−β阻害によるトリプルネガティブ乳がんの処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210196822A1 (https=) |
| EP (1) | EP3840776A4 (https=) |
| JP (1) | JP2021534195A (https=) |
| KR (1) | KR20210046716A (https=) |
| CN (1) | CN113271962A (https=) |
| AU (1) | AU2019325593A1 (https=) |
| BR (1) | BR112021003093A2 (https=) |
| CA (1) | CA3110276A1 (https=) |
| IL (1) | IL280958A (https=) |
| MX (1) | MX2021002006A (https=) |
| SG (1) | SG11202101663WA (https=) |
| WO (1) | WO2020041607A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230365653A1 (en) * | 2020-07-24 | 2023-11-16 | Mabwell (shanghai) Bioscience Co., Ltd. | Tgf-beta rii mutant and fusion protein thereof |
| CN121319180A (zh) * | 2020-07-28 | 2026-01-13 | 乐普生物科技股份有限公司 | 靶向PD-L1和TGF-β的双功能分子 |
| CN112640887B (zh) * | 2020-12-25 | 2022-05-13 | 武汉睿健医药科技有限公司 | 一种神经干细胞冻存液及其应用 |
| KR20230020041A (ko) | 2021-08-02 | 2023-02-10 | 숙명여자대학교산학협력단 | miR-181a 억제제 및 커큐민을 유효성분으로 포함하는 삼중음성유방암 치료용 조성물 |
| TW202330626A (zh) * | 2021-09-30 | 2023-08-01 | 大陸商貝達藥業股份有限公司 | 雙特異性抗體及其應用 |
| CN115671314A (zh) * | 2022-11-16 | 2023-02-03 | 中南大学 | 一种抗血管生成靶向黑磷纳米片的制备方法及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG166768A1 (en) * | 2003-12-23 | 2010-12-29 | Rinat Neuroscience Corp | Agonist anti-trkc antibodies and methods using same |
| WO2014205184A2 (en) * | 2013-06-19 | 2014-12-24 | University Of Miami | Classification system, methods and kit for classifying. predicting and treating breast cancer |
| US9676863B2 (en) * | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| WO2016145294A1 (en) * | 2015-03-12 | 2016-09-15 | The University Of Chicago | Methods for determining prognosis for breast cancer patients |
| CA3001903A1 (en) * | 2015-10-13 | 2017-04-20 | The Scripps Research Institute | Therapeutic targeting of casein kinase 1.delta. in breast cancer |
-
2019
- 2019-08-22 BR BR112021003093-0A patent/BR112021003093A2/pt not_active Application Discontinuation
- 2019-08-22 CA CA3110276A patent/CA3110276A1/en active Pending
- 2019-08-22 CN CN201980069495.4A patent/CN113271962A/zh active Pending
- 2019-08-22 JP JP2021509764A patent/JP2021534195A/ja active Pending
- 2019-08-22 KR KR1020217007924A patent/KR20210046716A/ko not_active Withdrawn
- 2019-08-22 MX MX2021002006A patent/MX2021002006A/es unknown
- 2019-08-22 AU AU2019325593A patent/AU2019325593A1/en not_active Abandoned
- 2019-08-22 SG SG11202101663WA patent/SG11202101663WA/en unknown
- 2019-08-22 WO PCT/US2019/047734 patent/WO2020041607A1/en not_active Ceased
- 2019-08-22 EP EP19851477.0A patent/EP3840776A4/en not_active Withdrawn
-
2021
- 2021-02-16 US US17/176,427 patent/US20210196822A1/en not_active Abandoned
- 2021-02-18 IL IL280958A patent/IL280958A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534195A5 (https=) | ||
| Hamid et al. | Intratumoral immunotherapy—update 2019 | |
| US20240390489A1 (en) | Methods of increasing strength and functionality with gdf8 inhibitors | |
| JP6837105B2 (ja) | Ｉｌ−４ｒ阻害剤の投与による好酸球性食道炎を治療する方法 | |
| CN112546217B (zh) | 用于治疗肿瘤的抗b7-h1抗体 | |
| RU2622021C2 (ru) | Лечение кахексии | |
| US20220273722A1 (en) | Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment | |
| CN109789196A (zh) | 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法 | |
| KR101910760B1 (ko) | 종양성 질병들에 대한 치료 | |
| US20260109766A1 (en) | Lag-3 antagonist therapy for melanoma | |
| JP2014500278A (ja) | 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与 | |
| KR20210046716A (ko) | 표적화된 TGF-β 억제에 의한 삼중 음성 유방암의 치료 | |
| CN102395602B (zh) | 在疾病治疗方法中使用的b‑淋巴细胞靶向剂 | |
| JPWO2020041607A5 (https=) | ||
| JP2021523096A5 (https=) | ||
| CN121622884A (zh) | 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途 | |
| KR20230121995A (ko) | 톨-유사 수용체 작용제를 사용한 암 요법 | |
| WO2021221668A1 (en) | Anti-sars-cov-2 monoclonal antibody compositions | |
| RU2021107205A (ru) | ЛЕЧЕНИЕ ТРОЙНОГО НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ ПУТЕМ НАПРАВЛЕННОГО ИНГИБИРОВАНИЯ TGF-β | |
| KR20190142398A (ko) | Il-17 길항제를 사용하여 천식을 선택적으로 치료하는 방법 | |
| JP2003522774A (ja) | 異種型抗体療法の効力の診断のための方法 | |
| CN115734971A (zh) | 抗ang-2抗体及其用途 | |
| CN114081945A (zh) | 一种治疗肿瘤疾病的联合用药组合物及应用 | |
| KR102834430B1 (ko) | 전신 투여용 종양용해성 단순 포진 바이러스를 포함하는 약학적 조성물 | |
| CN120248122A (zh) | 一种靶向uPAR的单链抗体、嵌合抗原受体及其应用 |